Among Matthew During's scientific advancements are the development of controlled release polymers for delivering drugs to the central nervous system; the development and characterization of a vaccine for stroke and epilepsy, for which he won two National Institutes of Health awards; and the development of the first autoregulatory genetic therapy for obesity and related metabolic disorders. Dr. During has authored and co-authored more than 200 research papers that have appeared in publications such as the Nature, The Lancet, Cell, and Science. He has co-edited two textbooks on gene therapy, and he has contributed chapters to 17 texts. Matthew During holds more than 35 patents and patent applications.
In addition to his research, Matthew During holds a number of academic and hospital appointments. He currently serves as Professor of Molecular Virology, Immunology, Medical Genetics, Neuroscience, and Neurosurgery at The Ohio State University; Professor of Molecular Medicine at the University of Auckland in New Zealand; and Visiting Professor of Translational Neuroscience at the University of Oxford in the United Kingdom. He has also taught at Yale University School of Medicine and Weill Medical College of Cornell University. Dr. During has been an Attending Physician at Yale-New Haven Hospital, Director of the CNS Gene Therapy Center at Jefferson Medical College, and Research Director in the Department of Neurological Surgery at Cornell.
Matthew During holds a Doctor of Medicine and Doctor of Science in Neuroscience and Genetics from the University of Auckland. He completed specialty fellowships at the Massachusetts Institute of Technology, Massachusetts General Hospital and Harvard Medical School, and Yale University School of Medicine. He is a Fellow of the American College of Physicians, the Royal Australasian College of Physicians, and the American Association for the Advancement of Science.